Document Detail


Relating statin therapy to C-reactive protein levels.
MedLine Citation:
PMID:  16086647     Owner:  NLM     Status:  PubMed-not-MEDLINE    
Abstract/OtherAbstract:
Inflammation is pivotal in atherosclerosis, and C-reactive protein (CRP) is an inflammatory marker that predicts cardiovascular events. The Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) trial compared the standard lowering of low-density lipoprotein (LDL)-cholesterol with pravastatin 40 mg/day, with the intense lowering of LDL-cholesterol with atorvastatin 80 mg/day on atheroma volume in patients with coronary artery disease, and showed that the atheroma progressed by 2.7% in the pravastatin group, and remained unchanged in the atorvastatin group. At 18 months follow-up, the CRP levels were reduced from a baseline level of 2.8 mg/l to 1.8 mg/l by atorvastatin, whereas pravastatin had little effect, and there was a good correlation between both the ultrasonographic progression of disease and the reduction in CRP levels. The Pravastatin or Atorvastatin Evaluation and Infection Therapy--Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) trial compared the long-term effects of the standard lowering of LDL-cholesterol with pravastatin, with the intense lowering of LDL-cholesterol with atorvastatin in patients with an acute coronary syndrome. The primary end point was the first of death, myocardial infarction, unstable angina requiring hospitalisation, revascularisation or stroke, and, at the end of 2 years, was greater in the pravastatin than the atorvastatin group (26.3 versus 22.4%, respectively). Patients with CRP levels of 2 mg/l had lower rates of recurrent myocardial infarction or death from coronary causes than patients with higher levels. Further analysis should be undertaken to assess cardiovascular risk at different levels of CRP, including assessing cardiovascular risk at different levels in men and women. Definitive results about the importance of lowering CRP levels are not likely to be obtained until the results of the Justification for Use of Statins in Primary Prevention, an Intervention Trial in Evaluating Rosuvastatin (JUPITER) study are published.
Authors:
Sheila A Doggrell
Related Documents :
7662447 - Serum lipids four weeks after acute myocardial infarction are a valid basis for lipid l...
16596807 - Lipid and non-lipid effects of statins.
9274947 - The possible role of remnant-like particles as a risk factor for sudden cardiac death.
2229757 - Plasma homocyst(e)ine levels in men with premature coronary artery disease.
8712627 - Effect of stenting on graft vascularization after laryngotracheoplasty.
18442727 - Off-pump exchange of short-term percutaneous ventricular assist device (vad) to long-te...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Expert opinion on pharmacotherapy     Volume:  6     ISSN:  1744-7666     ISO Abbreviation:  Expert Opin Pharmacother     Publication Date:  2005 Aug 
Date Detail:
Created Date:  2005-08-09     Completed Date:  2006-06-21     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100897346     Medline TA:  Expert Opin Pharmacother     Country:  England    
Other Details:
Languages:  eng     Pagination:  1597-600     Citation Subset:  -    
Affiliation:
Division of Health Practice, Auckland University of Technology-Akoranga Campus, Northcote, Auckland, New Zealand. doggrell@xtra.co.nz
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  An update of irbesartan and renin-angiotensin system blockade in diabetic nephropathy.
Next Document:  Treatment of dyslipidaemia in HIV-infected persons.